US 12,078,634 B2
Broad spectrum kinase binding agents
Cesear Corona, Paso Robles, CA (US); Poncho Meisenheimer, San Luis Obispo, CA (US); Matthew Robers, Madison, WI (US); and James Vasta, Madison, WI (US)
Assigned to Promega Corporation, Madison, WI (US)
Filed by Promega Corporation, Madison, WI (US)
Filed on Aug. 15, 2022, as Appl. No. 17/819,784.
Application 17/819,784 is a continuation of application No. 16/426,982, filed on May 30, 2019, granted, now 11,442,063.
Claims priority of provisional application 62/677,956, filed on May 30, 2018.
Prior Publication US 2023/0194515 A1, Jun. 22, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 239/48 (2006.01); G01N 1/34 (2006.01); G01N 33/543 (2006.01); G01N 33/573 (2006.01); G01N 21/64 (2006.01); G01R 33/56 (2006.01); G01T 1/164 (2006.01)
CPC G01N 33/54353 (2013.01) [C07D 239/48 (2013.01); G01N 1/34 (2013.01); G01N 33/573 (2013.01); G01N 21/6428 (2013.01); G01N 2021/6439 (2013.01); G01R 33/5601 (2013.01); G01T 1/1642 (2013.01)] 14 Claims
 
1. A broad-spectrum kinase binding agent attached to a fluorophore, comprising a kinase binding moiety of formula:

OG Complex Work Unit Chemistry
attached to the fluorophore.